



University of HUDDERSFIELD

University of Huddersfield Repository

Alcorn, J., Biyani, S., Weston, S., Sundaram, R., Burton, Rob, Topping, Annie and Stephenson, John

Retrospective analysis of patients' experience to intravesical Bacillus Calmette-Guerin (BCG)

Original Citation

Alcorn, J., Biyani, S., Weston, S., Sundaram, R., Burton, Rob, Topping, Annie and Stephenson, John (2015) Retrospective analysis of patients' experience to intravesical Bacillus Calmette-Guerin (BCG). In: EAU 15: European Association of Urology, 20th-24th March 2015, Madrid, Spain.

This version is available at <http://eprints.hud.ac.uk/id/eprint/23464/>

The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided:

- The authors, title and full bibliographic details is credited in any copy;
- A hyperlink and/or URL is included for the original metadata page; and
- The content is not changed in any way.

For more information, including our policy and submission procedure, please contact the Repository Team at: E.mailbox@hud.ac.uk.

<http://eprints.hud.ac.uk/>

Retrospective analysis of patients' experience to intravesical Bacillus Calmette-Guerin (BCG)

18

J. Alcorn ¹, S. Biyani ¹, P. Weston ¹, S. Sundaram ¹, R. Burton ², A. Topping ³, J. Stephenson ²

(1) Mid Yorkshire Hospitals NHS Trust, Dept. of Urology, Wakefield, United Kingdom, (2) University Huddersfield, Dept. of Human and Health Sciences, Huddersfield, United Kingdom, (3) Hamad Medical Corporation, Dept. of Nursing Education, Doha, Qatar

I. INTRODUCTION and OBJECTIVES

BCG treatment has been used for many years, but not without controversy (Paul et al., 2012). It is regarded as the gold standard for treating NMIBC (Babjuk et al., 2011; Paul et al., 2012). As low as 16%, complete what is seen as the best treatment available (Lamm et al., 2000). If the remaining 84% then progress to muscle invasive bladder cancer, this has consequences for the patient as well as the healthcare system.

The aim of this study was to analyse the reasons for treatment interruption in everyday clinical practice in a large district hospital.

II. MATERIALS & METHODS

Table 1 shows the demographics of the study population. Quantitative data regarding the clinical experiences of BCG treatment received by patients during the period 1st January 2004 to 31st December 2011 was collected through a retrospective case note analysis of 234 case notes. Patients with a diagnosis of NMIBC, grade 3 Ta/1 or CIS, aged 18 years or over were selected. The data from this convenience sample can be considered as representative data. The data extraction tool specifically designed for this study, was piloted to ensure validity and reliability. The data was analysed using IBM SPSS v20 for Windows.

Table 1: The age and gender of the population and course completion

Characteristic	N	%
Age (years)		
<59	28	(12)
60-69	66	(28)
70-79	111	(48)
>80	29	(13)
Gender		
Male	188	(80)
Female	46	(20)
Completed 1 year		
Yes	115	(49)
No	119	(51)
Completed 2 years		
Yes	40	(17)
No	194	(83)
Completed 3 years		
Yes	23	(10)
No	211	(90)
No days on treatment		
Range	1	2581
Mean	455.13	
Median	350.00	

Fig 1: Chart showing withdrawal from treatment by age group




Fig 2: Chart showing patients who withdrew from treatment early through symptoms or side effects




Fig 3: Chart comparing patients who were given the contact details of a nurse specialist with those who did not receive contact details





Fig 4: Chart comparing patients given written information with those who did not receive any written information



III. RESULTS

Table 1 shows that the sample of 234 patients were made up of 188 (80%) male and 46 (20%) female, 140 (61%) were 70 years or older. Also that 115 (49%) completed 1 year of treatment and 23 (10%) completed the full three years. Figures 1-4 show that patients who experienced side effects from the treatment were more likely to withdraw from the treatment early. Also those patients who received the contact details of a nurse specialist or written information were also likely to withdraw from treatment early.

IV. CONCLUSION

Our study demonstrated that severe toxicity resulted in discontinuation of therapy in the majority. There appears to be a withdrawal rate of 90%, higher than the literature and that the majority of these withdraw from treatment within the first year. The data shows that of those that experienced one or more side effect were more likely to withdraw from treatment. Also that age is an important factor to consider as those who were 70 or over were more likely to withdraw from treatment. A surprising factor is that these preliminary data suggest interruptions could be attributable to patient's counselling by a clinical nurse specialist and those who received written information.

REFERENCES

- Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E., Böhle, A., Palou, J., & Roupret, M. (2011). *Guidelines on non-muscle invasive bladder cancer (TaT1 and CIS)*. European Association of Urology.
- Lamm, D., Blumenstein, B., Crissman, J., Montie, J., Gottesman, J., Lowe, B., Sarosdy, M., Bohl, R., Grossman, H., Beck, T., Leimert, J. & Crawford, D. (2000). Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. *The Journal of Urology*, 163(4), 1124-9.
- Paul, A., Carey, B., Cross, B., Rock, C., & Singh, P. (2012). Guidelines for the Investigation and Treatment of Bladder, Renal and Prostate Cancers. *Yorkshire Cancer Network*. Retrieved October 16, 2012, from <http://www.yorkshire-cancer-net.org.uk/html/downloads/ycn-urology-bladder-renal-prostate-guidelines-sept2012-v2.0.pdf>